Shenzhen Kangtai Biological Products Co., Ltd. (SHENZHEN KANGTAI BIOLOGICAL PRO) aksje

Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus acellular pertussis and haemophilus influenzae type B combined vaccines; diphtheria, tetanus, and acellular pertussis combined vaccine, adsorbed; rabies vaccines (human diploid cell, freeze-dried) for human use; haemophilus influenzae type b conjugate vaccines; measles and rubella combined vaccines (live); SARS-CoV-2 vaccines (vero cell, inactivated); and COVID-19 vaccines (ChAdOx1-S recombinant). It also develops measles, mumps, and rubella vaccines; DTaP-Hib-IPV combined vaccines, 4-valent influenza (split) vaccines, and poliomyelitis vaccines (vero cells, inactivated for the Sabin strain). In addition, the company engages in general and special freight transportation; warehousing services; technology development; import and export of goods and technology; agency import and export; investment in and establishment of pharmaceutical projects and other industries; pharmaceutical technology development, information consulting, and leasing services for self-owned buildings and equipment; wholesale and trade of preventive biological products; technical services; technical consulting and exchange; technology transfer and promotion; and contract manufacturing of pharmaceutical products. It exports its products. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.